DK

Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results

Retrieved on: 
Thursday, May 9, 2024
Webcast, PIN, Q&A

20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024.

Key Points: 
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024.
  • Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall.
  • The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/ee4aippx .
  • A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/ .

APRIL VOLUMES: FREIGHT GROWTH ACROSS MOST OF NETWORK

Retrieved on: 
Wednesday, May 8, 2024
Road

In general, this decreases passenger volumes and increases freight volumes for the month compared to 2023.

Key Points: 
  • In general, this decreases passenger volumes and increases freight volumes for the month compared to 2023.
  • Ferry – freight: Total volumes in April 2024 were 13.9% above 2023 and up 10.1% adjusted for the addition of Strait of Gibraltar routes in 2024 and closure of the Calais-Tilbury route in 2023.
  • For the last twelve months 2024-23, the total transported freight lane metres decreased 0.9% to 39.7m from 40.1m in 2023-22.
  • The increase was 10.0% adjusted for the addition of Strait of Gibraltar routes.

Svitzer Completes Tug Series Delivery in Brazil

Retrieved on: 
Wednesday, May 8, 2024
Hall-effect thruster, FSRU, ASD, Shipbuilding

Rio de Janeiro – 07 May 2024 - Svitzer, a leading global towage provider, has today announced the successful delivery of Svitzer Babitonga, the final tug in a series of six sister vessels from the 2300 Rampart Series.

Key Points: 
  • Rio de Janeiro – 07 May 2024 - Svitzer, a leading global towage provider, has today announced the successful delivery of Svitzer Babitonga, the final tug in a series of six sister vessels from the 2300 Rampart Series.
  • Built by Brazilian shipyard Rio Maguari, Svitzer Babitonga is an Azimuth Stern Drive (ASD) tugboat from the 2300 Rampart Series.
  • “The delivery of the Svitzer Babitonga marks an important milestone in concluding the program of six newbuilds as a way to support our continuous growth journey in Brazil,” said Daniel Reedtz Cohen, Managing Director Svitzer Brazil.
  • The delivery of the Svitzer Babitonga reaffirms Svitzer's dedication to delivering reliable, sustainable, and safe marine services in Brazil and beyond.

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

Retrieved on: 
Tuesday, May 7, 2024
Therapy

This was achieved by the recent investor-initiated conversion of all outstanding Series A Preferred Stock into common stock, resulting in a single class of shares outstanding, and the conversion of 93% of the Company’s outstanding warrants, including all variable-priced warrants.

Key Points: 
  • This was achieved by the recent investor-initiated conversion of all outstanding Series A Preferred Stock into common stock, resulting in a single class of shares outstanding, and the conversion of 93% of the Company’s outstanding warrants, including all variable-priced warrants.
  • Following this reduction, the Company reports that only a limited number of warrants remain unexercised, specifically 256,667 warrants, each with a fixed exercise price of $20 per share.
  • Furthermore, the Company informs that it has fully paid off all bridge notes, totaling $1,746,630, including principal and accrued interest.
  • Understanding the investment case for biotech companies like ours can be complex for investors at all levels.

Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

Retrieved on: 
Monday, May 6, 2024
Security (finance), Form, Patient, Therapy, Ovarian cancer

The Company is in the process of obtaining official written confirmation from Nasdaq, which will reinstate its full compliance with Nasdaq listing requirements.

Key Points: 
  • The Company is in the process of obtaining official written confirmation from Nasdaq, which will reinstate its full compliance with Nasdaq listing requirements.
  • In line with this progress, Allarity plans to formally request the Securities and Exchange Commission (the “SEC”) to withdraw its Registration Statement on Form S-1 (File No.
  • This decision follows a thorough reassessment of the company’s financial position, reflecting the recent improvement in equity status.
  • Thomas Jensen, CEO of Allarity Therapeutics, stated, “I am confident in our ability to regain compliance with Nasdaq’s equity rule.

Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration

Retrieved on: 
Friday, May 3, 2024
Planetary health, Geography, Dietary supplement, Health, Growth, HMO, Novozymes, Drink

For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations.

Key Points: 
  • For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations.
  • In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator.
  • The organic sales growth in the first quarter is driven by both Food & Health Biosolutions and Planetary Health Biosolutions.
  • With 4% organic sales growth, we deliver in line with expectations for the first three months, and we continue to successfully move forward on the integration.

Three-month interim report (Q1) 2024 (unaudited) 

Retrieved on: 
Thursday, May 2, 2024
ALK, DKK, Growth, Capital market

Launch preparations continue to progress as planned ahead of the expected launches in 2024/25.

Key Points: 
  • Launch preparations continue to progress as planned ahead of the expected launches in 2024/25.
  • ALK is implementing a number of optimisation and prioritisation initiatives in 2024 to free up approximately DKK 250 million in 2025 for strategic growth investments and support of its earnings ambitions.
  • These initiatives are expected to entail one-off costs of approximately DKK 60 million in 2024, that have been included in the earnings outlook which is unchanged.
  • Commenting on the Q1 results, CEO Peter Halling said: “2024 started well for ALK.

Genmab Announces Financial Results for the First Quarter of 2024

Retrieved on: 
Thursday, May 2, 2024
USD, FDA, Pfizer, EDT, Priority review, AbbVie, Food, Risk, Annual report, Johnson & Johnson, DKK, Janssen, U.S. FDA, Risk management, Environment, Rituximab, Follicular lymphoma, Novartis, PDUFA, ADC, Patient, Acquisition, Interim, Lenalidomide, Daratumumab, Priority, BST, Pharmaceutical industry

Genmab is maintaining its 2024 financial guidance published on February 14, 2024.

Key Points: 
  • Genmab is maintaining its 2024 financial guidance published on February 14, 2024.
  • We expect to update our guidance no later than in connection with our second quarter 2024 earnings.
  • Genmab will hold a conference call to discuss the results for the first quarter of 2024 today, Thursday, May 2, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT.
  • Actual results or performance may differ materially from any future results or performance expressed or implied by such statements.

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
Monday, April 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
Monday, April 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.